Vifor Pharma AG
Vifor Pharma AG (VIFN.SW) Stock Competitors & Peer Comparison
See (VIFN.SW) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VIFN.SW | CHF 166.15 | +0.48% | 0 | N/A | N/A | N/A |
| SDZ.SW | CHF 61.68 | +0.78% | 26.7B | 37.80 | CHF 1.63 | +0.97% |
| EVT.SW | CHF 26.96 | N/A | 4.8B | -25.92 | -CHF 1.04 | N/A |
| SFZN.SW | CHF 77.90 | -1.64% | 3.4B | 20.39 | CHF 3.84 | +0.49% |
| PPGN.SW | CHF 23.90 | -2.45% | 879.2M | -28.35 | -CHF 0.94 | N/A |
| CURN.SW | CHF 23.90 | -8.08% | 119.9M | -27.74 | -CHF 0.84 | N/A |
| MER.SW | CHF 102.20 | +0.00% | 0 | 14.20 | CHF 7.20 | N/A |
Stock Comparison
VIFN.SW vs SDZ.SW Comparison March 2026
VIFN.SW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIFN.SW stands at 0. In comparison, SDZ.SW has a market cap of 26.7B. Regarding current trading prices, VIFN.SW is priced at CHF 166.15, while SDZ.SW trades at CHF 61.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIFN.SW currently has a P/E ratio of N/A, whereas SDZ.SW's P/E ratio is 37.80. In terms of profitability, VIFN.SW's ROE is +0.08%, compared to SDZ.SW's ROE of +0.10%. Regarding short-term risk, VIFN.SW is less volatile compared to SDZ.SW. This indicates potentially lower risk in terms of short-term price fluctuations for VIFN.SW.Check SDZ.SW's competition here